Angiogenesis, the development of new blood vessels, is necessary for tumor growth. Antiangiogenic therapies have recently received attention as a possible cancer treatment. The purpose of this study was to monitor the vascularity of induced tumors in rats using contrastenhanced ultrasound during anti-angiogenic therapy. Six rats with subcutaneously implanted R3230 murine mammary adenocarcinomas were treated with an orally administered anti-angiogenic agent (SU11657) beginning 28 days after tumor implantation (20 mg/kg BW once daily). Three additional tumor-bearing control rats were treated with an equivalent volume of vehicle alone. Sonographic evaluation of tumor blood flow was performed using a modified Siemens Sonoline Elegra equipped with a 5.0 MHz linear transducer prior to drug administration, during the first 51 hours following initial drug administration, and on days 8 and 15 after initiation of therapy. Tumor volumes were estimated at each time point using a prolate ellipsoid method from linear dimensions measured on the B-mode ultrasound image in the three major axes. A destruction-replenishment technique was used for tumor blood flow evaluation using a constant rate infusion of intravenously delivered ultrasound contrast media (Definity). A destructive pulse was fired first, followed by a chain of nondestructive pulses that allowed for visualization of vascular contrast agent replenishment.
Introduction
An adequate vascular bed is necessary for neoplasms to enlarge beyond 1-2 mm 3 (1). Tumor cells develop a vascular supply by stimulating the production of growth factors that diffuse to nearby pre-existing vessels and stimulate the endothelial cells. Once stimulated, the endothelial cells produce additional factors that increase vascular permeability and induce the proliferation of new endothelial cells toward the developing tumor. Vascular endothelial growth factor (VEGF) is one factor that initiates the proliferation of endothelial cells as well as increasing the permeability of the regional blood vessels, allowing the extravasation of plasma proteins and resulting in the formation of an extravascular fibrin gel conducive to neovascular growth (2). VEGF, along with many other pro-angiogenic factors, binds to receptors of the tyrosine kinase family (2, 3).
Previous reports have indicated that receptors of the tyrosine kinase family may be potential targets to inhibit angiogenesis (3). In vitro and in vivo trials using SU5416 (SUGEN Inc., South San Francisco, CA), a selective inhibitor of Flk-1/KDR, have resulted in decreased total and functional density of tumor microvasculature and restriction of tumor growth (4). More recently, in vitro and in vivo trials with SU11248 (SUGEN Inc., South San Francisco, CA), a more potent broad profile receptor tyrosine kinase (RTK) inhibitor, have resulted in cessation of tumor growth, and in many cases tumor regression (3). SU11657, used in the current study, is an indolinone compound closely related to SU11248, with similar selectivity and potency against RTKs.
Quantification of vascular function is of great interest in the evaluation of tumor development and response to these antiangiogenic treatments. Ultrasound imaging offers the major advantages of real-time vascular assessment and minimal invasiveness when compared to other methods used to assess perfusion. The advent of harmonic phase inversion imaging and intravascular ultrasound contrast agents has allowed for improved vascular visualization (5, 6) . In combination with phase inversion, subharmonic mode contrast-enhanced ultrasound has been described for evaluating microvasculature and estimating regional flow velocity (7) . The method used in this paper employs a destructive pulse followed by a series of non-destructive subharmonic phase inversion imaging frames, allowing for assessment of contrast agent replenishment (7) . Microvascular blood velocities on the order of 0.1-10 mm/sec, that are undetectable with traditional Doppler methods, can be detected with this technique (7).
This study was designed to assess tumor microvasculature during the administration of anti-angiogenic therapy using an ultrasound mode that combines subharmonic receiving frequencies, phase inversion, and destruction-replenishment techniques. Changes in tumor volume and enhancement characteristics in treated and control rats were made over time and compared to contrast-enhanced CT and histology.
Materials and Methods

Animal Model
All protocols were approved by the UC Davis Animal Use and Care Administrative Advisory Committee. Nine male 300-500 gm Fisher 344 rats were implanted with subcutaneous tumors in the dorsal lumbar region lateral to the spine. Rats were housed in standard cages and fed a commercial murine diet. Anesthesia was induced and maintained using aerosolized isoflurane (a). The mammary adenocarcinoma tumor line (b) was propagated by resecting a piece of tumor tissue approximately 1 mm 3 from a donor rat and implanting it through a stab incision made lateral to the spine of anesthetized recipient rats.
Six rats received an anti-angiogenic agent (c) beginning 28 days after tumor implantation and immediately after the first imaging session. A dose of 20 mg/kg/day administered via oral gavage was calculated using an allometric scaling technique (8). Three rats received vehicle control (CMC) using the same timing and dosing schedule. Rats were re-anesthetized and imaged at 6 hours, 24 hours, 2 days, 8 days and 15 days following the onset of treatment.
Ultrasound Imaging
Ultrasound images of tumors were obtained in anesthetized rats using a modified Sonoline Elegra (d) and a 5 MHz linear array transducer. Rats were positioned in sternal recumbency on a heating pad. The hair was clipped from the tumor region and a 24-gauge tail vein catheter (e) was placed for contrast infusion. Ultrasound coupling gel and a gel standoff were placed between the tumor surface and transducer. A standard B-mode image was recorded from which tumor length, width, and height were obtained at the maximum tumor dimensions. Tumor volume was calculated using the formula for a prolate ellipsoid: volume = π/6 * (length * width * height)
[1]
Ultrasound contrast media (f) was diluted with sterile physiologic saline to 130 µl/ml and infused at a constant rate of 10 ml/hour through the tail vein catheter. Imaging was delayed for approximately 2 minutes after the start of contrast infusion in order to reach a constant intravascular contrast medium concentration.
The ultrasound contrast agent within the imaging field was destroyed by a sequence of pulses before the replenishment of contrast agent within that region was visualized. The destructive pulses generate a peak negative transmission pressure of 2.2 MPa at 3 MHz (MI=1.27). Experimental work included in (9) indicates that this single destructive imaging pulse will destroy all microbubbles whose radii are less than 3 µm. The resting radius of the contrast agent used in this investigation is approximately Rayleigh-distributed with a mean radius of 1.0 µm, with 99% of bubbles having a radius less than 3 µm.
The non-destructive imaging mode is based on subharmonic oscillations generated by insonifying contrast agent microbubbles at a specific frequency and amplitude. Imaging with a transmission frequency of 6 MHz and reception with a narrow bandwidth centered at 3 MHz invokes a subharmonic response from bubbles whose radii range from 0.5 µm to 1.5 µm. Pulses with a center frequency of 6 MHz and peak negative pressure of 800 kPa (MI= .32) were used to interrogate the flowing contrast agent, producing minimal microbubble destruction. A pair of inverted pulses, including a rarefaction-first pulse and a compression-first pulse, is transmitted with an inter-pulse delay on the order of hundreds of microseconds. The two echoes from each pair were first summed, and the result of the first sum subtracted from all subsequent sums to yield a signal with a high contrast agent-to-tissue signal to noise ratio. Application of the subharmonic filter, the addition of phase inverted pulse pairs, and the subtraction of the first pulse pair from all remaining pairs resulted in the received signal for each pixel, r(t), within which tissue echoes are suppressed by approximately 27 dB. Signals for which r(t) does not exceed a threshold value r th (t) were set to zero, and we denote the signal train following the threshold by r * (t). By eliminating smaller signals, noise and flow in the surrounding muscle and skin regions were eliminated from the image.
Subharmonic phase-inversion images were acquired using a pulse sequence lasting a total of 34 seconds and including many time-delayed pulse pairs. Five destructive pulses were transmitted at 0.1-second delays, followed by a set of 29 nondestructive pulses. The first 10 non-destructive pulses are separated by 0.1 seconds, the following 10 are transmitted at 0.5-second intervals, and the final 9 are transmitted at 1-second intervals. This methodology allows the early time points to be sampled at a higher rate, so that the vessels with fast flow are sampled sufficiently, while the lower sampling rate for the later time points allows the slow flow to be monitored with fewer fired pulses (9). At least 3 complete 34-second acquisitions were obtained for each imaging plane, and at least 2 imaging planes near the center of the tumor were evaluated at each therapeutic time point. A parasagittal image of the kidney was also acquired using the destruction-replenishment mode to assure that adequate contrast media delivery was achieved. The echo from the destructive pulses were not used in the generation of the parametric images.
Various parameters were estimated in order to quantify the spatial extent and magnitude of the flow through the tumor region of interest (ROI). The temporal integral of the signal detected in each pixel was termed the integrated area under the curve (IAUC). A histogram of IAUC values was then produced. The zeroth moment of the histogram, M 0 , is the number of pixels within the ROI for which the integral of r * (t) over the pulse sequence exceeded a threshold. The first moment, M 1 , of the histogram is:
M 1 represents the temporal and spatial integral of contrast agent echoes from the tumor ROI. The mean IAUC within the ROI is the ratio of the first moment divided by the zeroth moment. The mean and standard deviation of the IAUC and the zeroth and first moments, as well as the percentage of enhancing pixels (zeroth moment divided by the total number of pixels in the tumor ROI), were calculated over each tumor region of interest, and parametric maps of IAUC were created.
Using a custom routine written in commercially-available technical computing software (g), the time to 80% maximum intensity for the signal r * (t) was also estimated on a pixel-bypixel basis. The replenishment time for contrast agents entering a sample volume was estimated using Prony's method based on a rising exponential signal model, where the parameter β is the exponential time constant (9). The replenishment time (in seconds) was then estimated by t 80% =ln (0.2)/β. A parametric image of the replenishment time was created. Pixels in the image for which the signal magnitude was above the threshold, but the signal increase was not monotonic, are indicated by red on the parametric image.
Computed Tomography
CT evaluation of the tumor was performed with a helical CT scanner (h) following ultrasound imaging. rat was placed into the gantry in sternal recumbency and contiguous 1.0 mm collimated images were obtained through the tumor and surrounding tissue in a plane as close as possible to the ultrasound image acquisition plane. The slice demonstrating the maximal tumor width and height was selected and all additional images were obtained at this site. Following administration of a 1-ml bolus of iodinated contrast media (i) (400 mg I/ml) through the tail vein catheter, serial static 1.0 mm images were obtained every 2 seconds for 1 minute.
The time to 80% maximal contrast enhancement was calculated using a custom routine written with commerciallyavailable technical computing software (g) on a pixel-bypixel basis, and parametric images were created. Subjective comparison between ultrasound-and CT-generated parametric images was performed.
Histology
Following ultrasound and CT imaging 15 days after the start of anti-angiogenic therapy, the rats were euthanized and tumors removed en bloc and fixed in 10% formalin. Sections representative of the imaging plane were prepared for light microscopic evaluation. All sections were evaluated by a pathologist. Hematoxylin and Eosin (H&E) stain was applied to assess overall tumor morphology and regional viability. Blood vessels were identified using immunostains for Factor VIII and CD 31 and a count of microvascular density was averaged for 3 100x fields.
The image of at least one representative H&E-stained section of each tumor was digitized. From this image, purple pixels, assumed to represent viable tumor cells, were counted using a custom analysis routine, and the fraction of viable tissue within this representative section from each tumor was calculated.
Statistical Analysis
Two-sample Student's t tests assuming equal variance were performed to compare the tumor volumes and the ultrasound-derived parameters from treated and control animals, as well as to compare the percentage change in each parameter relative to its pre-treatment value, at each time point. Paired t tests were used to compare parameters after therapy to pre-treatment values within each group. A P value less than 0.05 was considered significant.
Results
The mean volume of the control tumors before treatment was 876 mm 3 (range 412-1745 mm 3 ). On day 15, the mean control tumor volume was 5504 mm 3 (range 3391-9006 mm 3 ) representing a 637% increase in tumor volume over the duration of the study. The mean volume of the treated tumors before treatment was 857 mm 3 (range 229-1161 mm 3 ), not significantly different from the volume of the control group. On day 15, the mean volume of the treated tumors had increased slightly to 1114 mm 3 (range 269-2582 mm 3 ). Both the tumor volumes and percentage change in tumor volumes were significantly different between the treated and control groups on day 15 (P = 0.001 and 0.0001, respectively) ( Figure 1a ).
Ultrasound imaging data showed changes in all measures related to perfusion (Figure 1b ). Before treatment, the means of the mean IAUC, standard deviation of IAUC, zeroth moment, first moment, time to 80% replenishment, and color to red pixel ratio were not significantly different between the treated and control groups (all P > 0.1). Fifteen days after treatment, the two groups were significantly different in all of these measures with P < 0.05.
The mean percent change from baseline for the first and zeroth moments was calculated for all time points (Table I) 
Figure 1: a: The percent increase in volume is presented for the pre-treatment, 2-day, 8-day, and 15-day imaging time points demonstrating continued growth of the tumors of the control group. The size of the treated tumors did not change significantly. b: The average percent changes in the ultrasound-generated values from pre-treatment to day 15 of the mean IAUC, standard deviation of IAUC, zeroth moment, first moment, time to 80% replenishment, and color to red pixel ratio are depicted for treated and control groups. The treated group is represented in black and the control group is represented in gray. lar fluctuations were observed in the CT imaging data. However, ultrasound images of the kidneys at these time points did not indicate a significant fluctuation in contrast delivery. Starting 2 days after the initiation of treatment, a significant difference was seen in the percent change of the first and zeroth moment between the control and treated animals.
The percentage change in IAUC measures between pre-treatment and day 15 for the treated and control tumor groups demonstrated a difference between the groups (Figure 2 ). The treated tumors showed a significant 40% decrease in mean IAUC (P = 0.04) and 40% decrease in standard deviation of IAUC (P = 0.04). The zeroth moment was on average unchanged, and the first moment decreased by 30% but this change was not statistically significant. Over the same time period, the control tumors showed an average 168% increase in zeroth moment and 206% increase in first moment, and no significant change in the mean and standard deviation.
Many regions of ultrasound contrast enhancement did not fit an exponential refill model, indicating that very slow or irregular flow conditions were present. The ratio of "colored" pixels containing monotonically increasing signal to "red" pixels indicating irregular flow decreased in treated tumors and stayed constant in control tumors (Figure 3a) , with a significant difference between groups at day 15, P < 0.001 (Figure 3b) . The time to 80% maximum ultrasound contrast enhancement increased in 2 of the 3 control tumors and in all treated tumors (Figure 3c ). The percent change in time to 80% maximum enhancement over the 15 day interval demonstrated a significant difference between control and treated tumors with P = 0.02. of viable tumor in the control tumors calculated from the analysis of the H&E-stained images was 3.85 times that in the treated tumors, a significant difference (P = 0.05). The fraction of viable tumor within the control tumor boundaries was 1.4 times greater than that in the treated tumors, although this difference was not significant (P = 0.18). Subjectively, there was a greater ratio of necrosis to viable tumor in the treated cases relative to the untreated. The control tumors had larger vessels coursing between nests of viable tumor than the treated tumors. The number of vessels per 100x field was approximately doubled in the control tumors compared to the treated tumors, however, this difference was not statistically significant.
Ultrasound-generated parametric maps showed a qualitative change in vascular distribution in control and treated animals over the duration of the study from a nearly uniformly distributed network of vessels to a heterogeneous vessel distribution with central avascularity at later time points (Figure 4) . In both the control and treated tumors, the regions identified by histology as containing homogenously-distributed viable tumor cells correlate spatially with the regions containing an ultrasound signal above the threshold (Figures 4 and 5) .
Ultrasound-generated parametric maps of the time to 80% replenishment were subjectively similar to CT-generated parametric images of time to 80% maximal contrast enhancement. Although bolus dynamics and contrast agent behavior were different between the two modalities, regions of intense, rapid enhancement and minimal, slow enhancement were spatially correlated (Figures 6 and 7) .
Rat T-4 displayed increasing zeroth and first moments, similar to control animals, but had no corresponding increase in viable tumor volume. The time to 80% replenishment increased by only 6% over the 15-day study in this animal, Figure 4d . much less than any other value in the treated group. The histology of this lesion was atypical for either the treated or control groups, demonstrating small islands of viable tumor cells throughout the mass (Figure 8a) . The ultrasound parametric image of replenishment time mapped these islands of viable tumor (Figure 8b) , and the large number of red pixels throughout the image suggests heterogeneous flow with some areas of decreased viable tumor cell density.
Discussion
Various imaging strategies including contrast-enhanced MRI, contrast-enhanced computed tomography and nuclear imaging have been evaluated in the pursuit of a quantitative measure of tumor vascularity and perfusion. In particular, dynamic contrast-enhanced MRI using the integrated area under the curve technique has been validated using radioac-tive microspheres (10). Diagnostic ultrasound has the advantage of producing images in real-time with excellent temporal resolution. However, the task of mapping tumor vessels with ultrasound has previously been difficult because the acoustic signal from blood may be 34-40 dB below that of the surrounding vessel walls. Also, the flow rate in tumors may be significantly lower than in normal tissue due to the highly tortuous vessel structure and increased flow resistance (11). This low signal level and low flow rate prevent traditional Doppler techniques from being used to accurately assess tumor microvascular flow rates.
With the addition of intravascular microbubble contrast agents, ultrasound becomes sensitive to capillary-sized vessels and very low flow rates while maintaining the ability to detect morphological information from traditional B-mode imaging. Ultrasound contrast agents are non-diffusible microbubbles d: Corresponding CT-generated time to 80% maximal contrast enhancement map. Spatial similarities are seen between the ultrasound and CT generated parametric images with regions of rapid enhancement and slow enhancement distributed in the same pattern. surrounded by a synthetic shell. The microbubbles can be destroyed when subjected to ultrasound of appropriate frequency and sufficient pressure (12-14). Thus, a destructive pulse of ultrasound can be used to fragment the contrast agent within the region being imaged. Lower pressure, higher frequency, non-destructive pulses can be used to visualize the replenishment of contrast agent into the imaging region. The echo amplitude can be measured as the contrast agent fills the region and the rate of return can be estimated. Such a destruction and reperfusion method was described as early as 1998, where Wei et al. proposed the method for the assessment of blood flow velocity in the myocardium (15). Continued research has been performed in the assessment of reperfusion after acute myocardial infarction (15) (16) (17) (18) (19) (20) .
In a recent paper, a contrast-enhanced destruction-replenishment ultrasound scheme was described using subharmonic ultrasound imaging to improve spatial resolution and to differentiate echoes from the contrast agents and those from tissue (7). Sound is transmitted from the transducer at a specified frequency while the receiver is set to detect a subharmonic multiples of the original frequency. At clinically transmitted pressures, subharmonic echoes are generated by ultrasound contrast agents with minimal noise from surrounding tissue (21). Spatial resolution is on the order of 1 mm with temporal resolution on the order of 100 ms. Quantitative parametric maps of blood flow velocity and integrated enhancement can be generated using the information gathered from this system and appear to offer a wealth of information regarding regional vasculature. In particular, the time to 80% contrast replenishment was introduced as a robust parameter not affected by attenuation. Since this is a relative measure of the change in the echo intensity over the transmitted pulse train, it may overcome some limitations of previous efforts to quantify microvascular flow with ultrasound.
In the current study, parametric analysis of ultrasound data demonstrated a difference between control and SU11657treated groups. The spatial extent of contrast enhancement within the tumor ROI assessed by the zeroth moment increased over time in the control animals and not in the treated animals. The temporal and spatial integral of enhancement within the tumor ROI, assessed by the first moment, also increased over time in the control animals and not in the treated animals. The average enhancement (mean IAUC) decreased in treated animals and remained constant in controls. These findings suggest an overall decrease in the volume of blood flow in the treated animals secondary to decreased vessel numbers, differences in vessel size, fewer patent vessels or increased interstitial pressure. Presumably, the anti-angiogenic agent would decrease vascular permeability, making an increase in interstitial pressure less likely (3). Histological assessment of vessels by CD31 and Factor VIII immunostaining indicated a decrease, although not sta-tistically significant, in the number and size of the vessels in the treated group in comparison to controls. Several of the vessels in the intensely enhancing areas identified by ultrasound were large arteries, counted as only a single vessel in the histological assessment, which may explain why vessel counts were not higher in the corresponding high flow areas.
In addition, veins were visualized in the low flow areas. We speculate that, although these veins were counted in the vessel density measures, they could have been collapsed but not have contained blood flow.
One treated animal (T-4) showed an increase in the zeroth and first moments and no change in replenishment time, similar to control animals. The cause for the difference in behavior of this tumor is unclear. It is possible that this tumor had persistent high blood flow because it was not completely responding to the anti-angiogenic therapy. It is foreseeable that the level of drug uptake in this individual differed from others within the treated group or that the behavior of this tumor is a reflection of inter-individual variation. It is interesting to note that although the flow characteristics of this tumor were different from other treated tumors, the growth of the tumor was still truncated (increasing 29% over the study, which is near the mean for the treated group). Regardless, the histological features of this tumor demonstrated many persistent islands of tumor throughout its area. This correspondence between histology and ultrasound-generated flow maps is promising in regards to the ability of contrast-assisted ultrasound to detect different or incomplete responses to biologically active therapies.
New ultrasound-derived parameters described here include the time to 80% contrast replenishment, a robust parameter chosen to eliminate any effect of ultrasound attenuation. This parameter is based on the contrast replenishment model previously described by Wei, et al. (15) . Contrast media replenishes an image following a destructive pulse with estimates of blood flow approximating A * β, where A is the maximal signal intensity and β is the exponential rise of signal intensity (15). While the mean time to 80% replenishment was the same at baseline between the control and treated tumors (7.8 seconds), a significant difference in the mean time to 80% replenishment was observed after 15 days (8.0 seconds control, 11.2 seconds treated, P = 0.008). This slow image enhancement in the treated tumors, together with the low value for the temporal and spatial enhancement integral (first moment), suggest a low volume of blood flow. Future studies will compare this parameter to those used in previous studies with contrast ultrasound.
The relative volume over which the echo enhancement increases in a monotonic fashion was also reported, and shown to differ significantly between control and treated tumors. While the ratio of colored to red pixels was similar at baseline, this ratio remained unchanged in the control tumors and decreased in the treated tumors. The percent change in the ratio of colored to red pixels in the treated tumors was significantly different from the control tumors (P=0.001). The ability to assess the enhancement characteristics in each very small volume is an advantage of the ultrasound techniques presented in this report. With the local destruction of the contrast agent and the estimation of the signal enhancement curve for each small volume, regional variations in blood flow characteristics can potentially be assessed with this technique.
The growth rate showed a striking difference between treated and control tumors, indicating that the tumor was altered significantly by administration of SU11657. The 637% increase in tumor volume in the control group is consistent with previous observations of this tumor cell line by the authors. Treated tumors grew at a much slower rate, increasing in size by only 24% on average. A recent report involving the closely related compound SU11248 evaluated the effective plasma concentration and duration at various dosing schedules (3). Tumor growth delay, stasis, or regression was visible in athymic mouse models at 40 mg/kg/day, a higher dose than that used here. By allometric scaling, the dose of 20 mg/kg/day used here as the daily dose for rats is equivalent to the efficacious dose in mice. Higher doses of SU11657 may confer a more striking anti-angiogenic effect. Also, because we have not characterized the expression of SU11657 molecular targets in the R3230 cell line, we do not know the extent to which these targets contribute to tumor growth in this model.
It is unclear why the ultrasound and CT-generated data showed such marked fluctuations during the first 3 imaging sessions. In particular, the origin of the increase in the first and zeroth moments at the 24-hour time point (also observed subjectively in CT data) is unclear. Anesthesia-induced changes to the hydration status or blood pressure of the animals may be a contributing factor. Images of flow within the kidney cortex acquired at the same time points did not demonstrate this significant increase.
Three images were acquired within each plane, at immediately sequential time points, and therefore separated by 34 seconds. Variability (typically 10-20%) was present between parametric images of the same tumor in the same plane during a given imaging session. Some of this variability can be attributed to the fact that the imaging sequence was not synchronized with the cardiac cycle. Increases in contrast enhancement between sequences can also occur when systemic equilibrium of contrast media was not reached prior to the onset of data acquisition. A decrease in enhancement can be produced by the destruction of the contrast agent within nearby feeder vessels. The tumors demonstrating the greatest percent variability were those with the smallest enhancement. It is likely that the low enhancement regions are near the threshold established to eliminate noise.
Regardless, the change in vessel distribution was visible in both the control and treated groups. It has been shown that many tumors outgrow their blood supply and develop central regions of necrosis, as observed in our control group. However, the progression from diffuse vascularity to a peripheral distribution in the treated group must stem from other causes since the growth of these tumors was relatively small. In a previous report, although tumors treated with SU11248 remained constant in size by caliper measurement, the percentage of viable tumor as determined by photon emission imaging and correlated histology decreased (3). Contrast-enhanced ultrasound allowed for visualization of vascular distribution and re-distribution during anti-angiogenic therapy and may have been demonstrating this decrease in viable tumor volume.
Dynamic contrast-enhanced CT imaging was chosen as a compliment to contrast-enhanced ultrasound because the use of contrast-enhanced CT has been well documented (22) (23) (24) (25) (26) . The speed and degree of tissue enhancement has been shown to correlate well with vascular distribution within the tumor (22). One limiting factor to CT for quantitative blood flow assessment is the diffusible nature of traditional iodinated contrast media. Tumor vessels exhibit high permeability, which results in extravasation of iodine. Therefore, an indirect relationship exists between the degree of contrast enhancement and blood flow to a region. Ultrasound contrast media is entirely intravascular and thus better represents regional intravascular blood flow. Nonetheless, the similarities between enhancement observed with CT and ultrasound are encouraging.
In conclusion, this pilot study demonstrates an approach for evaluating the efficacy of anti-angiogenic agents such as SU11657. Contrast-enhanced ultrasound offers the advantages of sub-millimeter imaging resolution, intravascular contrast agent distribution, and a real-time imaging capability while remaining minimally invasive and allowing for serial evaluations. Quantifiable measures of the spatial extent and magnitude of contrast enhancement were significantly different between control and SU11657-treated tumors in this small study of a rat model.
